We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Drug of choice

25 April 2018 By Jeffrey Goldfarb

The Japanese drugmaker’s fifth proposal for its Irish rival sweetens the bid to some $64 bln. The headline value, which uses a huge pile of stock for currency, is falling fast as Takeda shareholders recoil. That creates an opening for other suitors who can offer more hard cash.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)